MedTrace Logo

NUC-3373 in Advanced Solid Tumours

NCT02723240 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2024-02-14

No results posted yet for this study

Summary

A two-part, phase I open label, dose escalation and expansion study to assess safety, pharmacokinetics and clinical activity of NUC-3373, a nucleotide analogue, in participants with advanced solid tumours.

Conditions

Interventions

DRUG

NUC-3373

Sponsors & Collaborators

  • University of Oxford

    lead OTHER

Principal Investigators

  • Sarah P Blagden, PhD, FRCP · University of Oxford

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2020-02-24
Completion
2021-02-24

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02723240 on ClinicalTrials.gov